Literature DB >> 16196486

Genetic targeting strategies for adenovirus.

Sam C Noureddini1, David T Curiel.   

Abstract

Adenovirus serotype 5 (Ad5) continues to be regarded as a gene delivery vehicle of high utility for a variety of clinical applications. However, targeting of the virus to alternate, non-native receptors has become a mandate for many gene therapy approaches, as inefficient viral transduction of target tissues has proven detrimental to the utility of Ad5. Thus, various targeting strategies have been endeavored to the end of highly specific cellular transduction, including that of genetic manipulation of the viral capsid. Modification of the tropism-determining fiber protein and other capsid locales has allowed vectorologists to develop vectors that are highly superior to the first-generation adenoviruses employed for gene therapy. Herein, the various genetic targeting strategies for Ad5 are reviewed, and the various schemas in which targeted transduction has been achieved with tropism-modified vectors are outlined.

Mesh:

Year:  2005        PMID: 16196486     DOI: 10.1021/mp050045c

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  27 in total

1.  Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine.

Authors:  Basav N Hangalapura; Dinja Oosterhoff; Tarun Gupta; Jan de Groot; Pepijn G J T B Wijnands; Victor W van Beusechem; Joke den Haan; Thomas Tüting; Alfons J M van den Eertwegh; David T Curiel; Rik J Scheper; Tanja D de Gruijl
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

Review 2.  Progress on adenovirus-vectored universal influenza vaccines.

Authors:  Kui Xiang; Guan Ying; Zhou Yan; Yan Shanshan; Zhang Lei; Li Hongjun; Sun Maosheng
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity.

Authors:  Anja Krause; Ju H Joh; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal; Stefan Worgall
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

4.  Phylogenetic analysis and structural predictions of human adenovirus penton proteins as a basis for tissue-specific adenovirus vector design.

Authors:  Ijad Madisch; Soeren Hofmayer; Christian Moritz; Alexander Grintzalis; Jens Hainmueller; Patricia Pring-Akerblom; Albert Heim
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

5.  Crystallization of the head and galectin-like domains of porcine adenovirus isolate NADC-1 fibre.

Authors:  Pablo Guardado-Calvo; Antonio L Llamas-Saiz; Gavin C Fox; Joel N Glasgow; Mark J van Raaij
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-10-30

6.  Implications of the innate immune response to adenovirus and adenoviral vectors.

Authors:  Seth M Gregory; Shoab A Nazir; Jordan P Metcalf
Journal:  Future Virol       Date:  2011-03       Impact factor: 1.831

7.  Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters.

Authors:  Birgit Dreier; Annemarie Honegger; Christian Hess; Gabriela Nagy-Davidescu; Peer R E Mittl; Markus G Grütter; Natalya Belousova; Galina Mikheeva; Victor Krasnykh; Andreas Plückthun
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-19       Impact factor: 11.205

8.  Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha.

Authors:  Weibo Cai; Zachary J Kerner; Hao Hong; Jiangtao Sun
Journal:  Biochem Insights       Date:  2008-07-22

Review 9.  Gene therapy of benign gynecological diseases.

Authors:  Memy H Hassan; Essam E Othman; Daniela Hornung; Ayman Al-Hendy
Journal:  Adv Drug Deliv Rev       Date:  2009-05-13       Impact factor: 15.470

10.  A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo.

Authors:  Erin E Thacker; Masaharu Nakayama; Bruce F Smith; R Curtis Bird; Zhanat Muminova; Theresa V Strong; Laura Timares; Nikolay Korokhov; Ann Marie O'Neill; Tanja D de Gruijl; Joel N Glasgow; Kenzaburo Tani; David T Curiel
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.